ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年8月18日

查看全文
  • Michela Gottardi Zamperla,
  • Barbara Illi,
  • Veronica Barbi,
  • Chiara Cencioni,
  • Daniele Santoni,
  • Stella Gagliardi,
  • Maria Garofalo,
  • Gabriele Antonio Zingale,
  • Irene Pandino,
  • Diego Sbardella,
  • Lina Cipolla,
  • Simone Sabbioneda,
  • Antonella Farsetti,
  • Chiara Ripamonti,
  • Gianluca Fossati,
  • Christian Steinkühler,
  • Carlo Gaetano,
  • Sandra Atlante

摘要

Background

Histone deacetylases (HDACs) are crucial regulators of gene expression, DNA synthesis, and cellular processes, making them essential targets in cancer research. HDAC6, specifically, influences protein stability and chromatin dynamics. Despite HDAC6’s potential therapeutic value, its exact role in gene regulation and chromatin remodeling needs further clarification. This study examines how HDAC6 inactivation influences lysine acetyltransferase P300 stabilization and subsequent effects on chromatin structure and function in cancer cells.

Methods and results

We employed the HDAC6 inhibitor ITF3756, siRNA, or CRISPR/Cas9 gene editing to inactivate HDAC6 in different epigenomic backgrounds. Constantly, this inactivation led to significant changes in chromatin accessibility, particularly increased acetylation of histone H3 lysines 9, 14, and 27 (ATAC-seq and H3K27Ac ChIP-seq analysis). Transcriptomics, proteomics, and gene ontology analysis revealed gene changes in cell proliferation, adhesion, migration, and apoptosis. Significantly, HDAC6 inactivation altered P300 ubiquitination, stabilizing P300 and leading to downregulating genes critical for cancer cell survival.

Conclusions

Our study highlights the substantial impact of HDAC6 inactivation on the chromatin landscape of cancer cells and suggests a role for P300 in contributing to the anticancer effects. The stabilization of P300 with HDAC6 inhibition proposes a potential shift in therapeutic focus from HDAC6 itself to its interaction with P300. This finding opens new avenues for developing targeted cancer therapies, improving our understanding of epigenetic mechanisms in cancer cells.